Thiogenesis Therapeutics (TSXV: TTI) 

Developing New Chemical Entities (NCEs) that are thiol compounds with strong antioxidant and anti-inflammatory properties and that have the potential to be used as new therapeutic drugs for mitochondrial diseases, including metabolic diseases such as diabetes, fatty liver, and cardiovascular disease. 

• Experienced leadership with a track record of successfully developing and launching orphan drugs, including thiols like TTI-0102
• Cost and time efficient model to achieve significant human efficacy data:
  
  • Prodrug, 505 (b)(2) regulatory pathway in the US
  • Small confirmatory human efficacy trials
  • Large pediatric markets with unmet medical needs  

• Significant evidence that the active moiety (cysteamine) showed efficacy in multiple indications but had dose-limiting side effects
• Phase 1 data has already demonstrated that TTI-0102 is well-tolerated at high doses
• Planned Phase 2 trials in MELAS, Leigh syndrome and pediatric MASLD/MASH